Conversionof Registered Series J Shares to Bearer Shares

CurrentReport No.: 17/2024

Date:August 19, 2024

LegalBasis: Article 17(1) of the MAR Regulation - Confidential Information.

TheManagement of Medicalgorithmics S.A., based in Warsaw (_quot;Company_quot;;_quot;Issuer_quot;), informs that on August 19, 2024, a resolution was adoptedregarding the conversion of registered ordinary Series J shares intobearer ordinary shares (_quot;Resolution_quot;). By virtue of the aforementionedResolution, the Company's Management, acting on the basis of §5(4)sentence 2 of the Company's Articles of Association and Article 334 §2of the Commercial Companies Code, at the request of the Company'sshareholder - Biofund Capital Management LLC (_quot;Shareholder_quot;), converted1,194,331 registered Series J shares with a nominal value of PLN 0.10each from registered ordinary shares to bearer ordinary shares in thesame number: 1,194,331.

Beforethe conversion, the Series J shares were registered ordinary shares, andafter the conversion, they became bearer ordinary shares belonging tothe Shareholder. The amount of the Company's share capital after theconversion remains unchanged at PLN 995,276.90. The total number ofvotes at the Company's general meeting after the conversion also remainsunchanged at 9,952,769.

TheCompany reminds that in current report No. 55/2022 dated October 1,2022, it informed that 4,976,384 shares, which were subscribed byBiofund Capital Management LLC, based in Miami (USA), in accordance withthe investment agreement dated October 1, 2022, between the Company andBiofund Capital Management LLC, are to be introduced to stock markettrading under the applicable exceptions from the obligation to prepare aprospectus, with the planned date for introducing all these shares totrading set for the end of 2026. Under this procedure, in June 2023,995,276 bearer ordinary Series I shares of the Company were alreadyadmitted to stock market trading, as indicated in current report No.14/2023 dated June 14, 2023. This conversion of shares at theShareholder's request was also carried out in execution of theprovisions of this investment agreement, i.e., for the purpose ofintroducing Series J shares to stock market trading without theobligation to prepare a prospectus, as indicated in current report No.55/2022 dated October 1, 2022.